Stock listing
Dusseldorf:TCE2 Celldex Therapeutics, Inc. Aktie
German listing (Dusseldorf) of Celldex Therapeutics, Inc. · home listing NASDAQ:CLDX
Follow Celldex Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CLDX
$27.42 USD -0.13 (-0.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CLDX
- Day range
- $26.64 – $28.43 USDNov 20, 2026
- Volume
- 1.72M sharesNov 20, 2026
- Market cap
- $2.15B USDAt the close on Nov 20, 2026 · price × 78.55M shares outstanding
- 52-week range
- $22.33 – $45.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $43.04M USDMedian day 924,313 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CLDX · Home | $27.42 USD | -0.13 (-0.5%) | 1,715,751 | $27.05 | $28.43 | $26.64 | $27.55 | Close on Nov 20, 2026 |
| Frankfurt:TCE2 | €24.82 EUR | +0.05 (+0.2%) | — | €24.82 | €24.82 | €24.82 | €24.77 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLDX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $27.42 | -0.13 | -0.5% | $27.05 | $28.43 | $26.64 | 1,715,751 | |
| $27.55 | -0.49 | -1.7% | $27.99 | $28.65 | $27.45 | 679,608 | |
| $28.04 | -0.55 | -1.9% | $28.77 | $29.31 | $27.50 | 520,500 | |
| $28.59 | -0.24 | -0.8% | $28.59 | $29.08 | $28.33 | 572,353 | |
| $28.83 | +0.30 | +1.1% | $28.41 | $28.95 | $28.00 | 544,313 | |
| $28.53 | -1.62 | -5.4% | $29.72 | $30.01 | $28.46 | 867,083 | |
| $30.15 | -0.50 | -1.6% | $30.86 | $31.10 | $30.14 | 589,058 | |
| $30.65 | -0.59 | -1.9% | $31.10 | $31.71 | $30.52 | 820,579 | |
| $31.24 | +1.37 | +4.6% | $30.52 | $31.66 | $29.42 | 1,858,087 | |
| $29.87 | +1.60 | +5.7% | $27.85 | $30.15 | $27.82 | 924,313 | |
| $28.27 | -1.66 | -5.5% | $29.90 | $30.00 | $28.21 | 1,110,690 | |
| $29.93 | +0.22 | +0.7% | $30.53 | $30.92 | $28.78 | 749,135 | |
| $29.71 | +0.67 | +2.3% | $29.36 | $29.95 | $28.67 | 871,967 | |
| $29.04 | -1.06 | -3.5% | $30.10 | $30.15 | $28.61 | 956,132 | |
| $30.10 | +0.21 | +0.7% | $29.70 | $30.12 | $29.20 | 870,775 | |
| $29.89 | +0.23 | +0.8% | $29.79 | $30.39 | $29.47 | 916,683 | |
| $29.66 | -0.49 | -1.6% | $29.63 | $30.02 | $28.92 | 899,157 | |
| $30.15 | +0.65 | +2.2% | $29.50 | $30.40 | $29.33 | 746,577 | |
| $29.50 | +0.25 | +0.9% | $29.90 | $29.90 | $28.99 | 593,361 | |
| $29.25 | +0.28 | +1.0% | $28.95 | $29.38 | $28.20 | 879,733 | |
| $28.97 | -0.40 | -1.4% | $29.08 | $29.73 | $28.49 | 877,932 | |
| $29.37 | -0.92 | -3.0% | $30.29 | $30.72 | $29.31 | 1,117,525 | |
| $30.29 | +0.62 | +2.1% | $29.99 | $30.82 | $29.61 | 1,100,405 | |
| $29.67 | +2.14 | +7.8% | $27.73 | $29.85 | $27.50 | 1,719,333 | |
| $27.53 | -1.40 | -4.8% | $28.89 | $28.89 | $27.47 | 997,900 | |
| $28.93 | +1.09 | +3.9% | $28.05 | $28.95 | $27.65 | 1,181,700 | |
| $27.84 | -0.41 | -1.5% | $28.49 | $28.73 | $27.68 | 1,044,300 | |
| $28.25 | -1.18 | -4.0% | $29.28 | $29.28 | $27.92 | 1,897,900 | |
| $29.43 | -0.46 | -1.5% | $29.61 | $30.03 | $28.99 | 596,400 | |
| $29.89 | +0.59 | +2.0% | $29.04 | $30.26 | $28.88 | 992,700 | |
| $29.30 | -1.13 | -3.7% | $30.07 | $30.10 | $28.63 | 3,950,400 | |
| $30.43 | -0.58 | -1.9% | $30.62 | $31.35 | $30.11 | 1,746,900 | |
| $31.01 | -1.58 | -4.8% | $32.68 | $32.68 | $30.85 | 1,768,200 | |
| $32.59 | +0.94 | +3.0% | $31.83 | $32.88 | $31.50 | 1,257,900 | |
| $31.65 | -0.53 | -1.6% | $32.26 | $32.54 | $30.98 | 2,404,700 | |
| $32.18 | -0.23 | -0.7% | $32.26 | $32.55 | $31.70 | 1,442,300 | |
| $32.41 | +0.77 | +2.4% | $31.71 | $32.76 | $31.45 | 2,502,000 | |
| $31.64 | +0.15 | +0.5% | $31.49 | $31.79 | $31.00 | 2,029,400 | |
| $31.49 | +0.39 | +1.3% | $31.06 | $32.15 | $30.38 | 1,824,100 | |
| $31.10 | -0.38 | -1.2% | $31.48 | $31.71 | $30.65 | 2,023,800 | |
| $31.48 | +0.36 | +1.2% | $31.48 | $31.66 | $30.59 | 2,297,500 | |
| $31.12 | -2.39 | -7.1% | $33.54 | $33.59 | $30.41 | 4,235,600 | |
| $33.51 | -4.38 | -11.6% | $36.60 | $38.39 | $30.39 | 12,888,900 | |
| $37.89 | -0.35 | -0.9% | $41.62 | $41.62 | $37.48 | 549,500 | |
| $38.24 | -0.74 | -1.9% | $38.87 | $38.87 | $37.54 | 2,081,900 | |
| $38.98 | +0.27 | +0.7% | $39.47 | $40.66 | $38.92 | 1,278,900 | |
| $38.71 | +0.20 | +0.5% | $38.59 | $39.21 | $38.25 | 1,001,400 | |
| $38.51 | -0.67 | -1.7% | $39.00 | $39.19 | $37.74 | 686,400 | |
| $39.18 | +2.28 | +6.2% | $37.40 | $39.42 | $37.27 | 1,000,200 | |
| $36.90 | -1.20 | -3.1% | $38.39 | $38.59 | $36.84 | 1,033,500 | |
| $38.10 | -0.68 | -1.8% | $38.78 | $38.86 | $37.75 | 949,000 | |
| $38.78 | -0.34 | -0.9% | $38.95 | $40.04 | $38.67 | 588,400 | |
| $39.12 | -0.56 | -1.4% | $38.78 | $39.87 | $38.50 | 834,300 | |
| $39.68 | +0.31 | +0.8% | $38.96 | $39.81 | $38.90 | 414,500 | |
| $39.37 | -0.11 | -0.3% | $39.50 | $39.89 | $38.95 | 418,000 | |
| $39.48 | +0.24 | +0.6% | $39.43 | $40.55 | $39.01 | 476,400 | |
| $39.24 | -0.39 | -1.0% | $39.13 | $39.90 | $38.94 | 542,500 | |
| $39.63 | +0.51 | +1.3% | $38.86 | $39.84 | $38.74 | 696,900 | |
| $39.12 | -1.34 | -3.3% | $40.33 | $40.57 | $39.04 | 424,900 | |
| $40.46 | -0.11 | -0.3% | $40.44 | $41.00 | $40.02 | 450,000 | |
| $40.57 | -0.65 | -1.6% | $41.18 | $42.12 | $40.06 | 540,700 | |
| $41.22 | +0.65 | +1.6% | $41.02 | $41.92 | $40.63 | 550,900 | |
| $40.57 | +0.19 | +0.5% | $40.16 | $40.98 | $39.53 | 416,900 | |
| $40.38 | +0.44 | +1.1% | $40.38 | $41.24 | $40.12 | 837,700 | |
| $39.94 | -1.76 | -4.2% | $41.40 | $42.00 | $39.45 | 1,002,500 |
Splits
2 splits since 2008 · NASDAQ:CLDX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-12 | Consolidation |
- Ticker
- Dusseldorf:TCE2
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Latest deck · Sep 22, 2026
Technical Presentation (September 2026)
Technical · 21 slides
Latest news
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Nov 19, 2026
Closed $27.42 (-0.5%) on Nov 20, 2026
Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)
Nov 5, 2026
Closed $29.87 (+5.7%) on Nov 6, 2026
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $29.87 (+5.7%) on Nov 6, 2026
Celldex to Present at Upcoming Investor Conferences
Nov 4, 2026
Closed $28.27 (-5.5%) on Nov 5, 2026
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Sep 22, 2026
Closed $33.51 (-11.6%) on Sep 22, 2026
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $41.71 (+0.4%) on Aug 7, 2026
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Jul 21, 2026
Closed $34.77 (-2.5%) on Jul 22, 2026
Celldex Announces Planned Transition of Chief Financial Officer
Jul 15, 2026
Closed $35.40 (-7.6%) on Jul 16, 2026
Celldex Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 150 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 5 calls with a replay · 5 with a transcript · latest Jun 12, 2025
- Decks
- 14 decks · latest Sep 22, 2026
Where Celldex Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CLDX · Home listing | NASDAQ | United States | USD |
| gettex:TCE2 | gettex | Germany | EUR |
| Lang & Schwarz:A2PEAB | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PEAB | LS Exchange | Germany | EUR |
| Tradegate:TCE2 | Tradegate | Germany | EUR |
| BOATS:CLDX | BOATS | United States | USD |
| BX Swiss:TCE1 | BX Swiss | Switzerland | CHF |
| Dusseldorf:TCE2 · This page | Dusseldorf | Germany | EUR |
| Frankfurt:TCE2 | Frankfurt | Germany | EUR |
| Munich:TCE2 | Munich | Germany | EUR |
| Stuttgart:TCE2 | Stuttgart | Germany | EUR |
Valuation
Price/book 3.3× against a median of 6.9×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.50B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.26B | US$2.03B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.8M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.00B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Regencell Bioscience Holdings Limited · NASDAQ:RGC | US$2.07B | US$2.06B | n/a | n/a | n/a | 155× | n/a | 0.0× | 1.57 |
| Hanall Biopharma Co., Ltd. · KRX:009420 | US$2.05B | US$2.03B | n/a | 16.7× | 335× | 16.9× | −15.3% | 0.1× | n/a |
| Median of the others | US$2.19B | US$1.87B | 108× | 16.7× | 212× | 6.9× | −15.3% | 0.0× | 1.46 |
Forecasts
12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 64.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.05 · 9 analysts
- Revenue, year to Dec 2026
- 1.43M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Anthony S. Marucci | Founder, President, Chief Executive Officer and Director |
| Denice Torres | Chief Executive Officer; The Ignited Company |
| Garry Neil | Chief Executive Officer; Chair of the Board, Avalo Therapeutics |
| Sam Martin | Senior Vice President and Chief Financial Officer |
| Cheryl L. Cohen | President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc. |
| Freddy A. Jimenez | Senior Vice President and General Counsel |
| Elizabeth Higgins | Executive Director, Investor Relations & Corporate Communications |
| Diane C. Young | Senior Vice President and Chief Medical Officer |
| Elizabeth Crowley | Senior Vice President, Chief Product Development Officer |
| Margo Heath-Chiozzi | Senior Vice President, Regulatory Affairs |
| Ronald A. Pepin | Senior Vice President and Chief Business Officer |
| Sarah Cavanaugh | Senior Vice President, Corporate Affairs and Administration |
| Teri Lawver | Senior Vice President, Chief Commercial Officer |
| Tibor Keler | Founder, Executive Vice President and Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Garry Neil | Chief Executive Officer; Chair of the Board, Avalo Therapeutics |
| Anthony S. Marucci | Founder, President, Chief Executive Officer and Director |
| Elizabeth Higgins | Executive Director, Investor Relations & Corporate Communications |
Events
Calls
| Call | When | Status |
|---|---|---|
| Celldex Therapeutics (NASDAQ:CLDX) Q1 2025 Earnings Call | Thu, Jun 12, 2025 · 6:00 PM ET | Replay |
| Celldex Therapeutics (NASDAQ:CLDX) Q4 2021 Earnings Call | Mon, Feb 28, 2022 · 4:30 PM ET | Replay |
| Celldex Therapeutics (NASDAQ:CLDX) Q2 2020 Earnings Call | Thu, Aug 06, 2020 · 4:30 PM ET | Replay |
| Celldex Therapeutics (NASDAQ:CLDX) Q2 2019 Earnings Call | Thu, Aug 08, 2019 · 4:30 PM ET | Replay |
| Celldex Therapeutics (NASDAQ:CLDX) Q4 2018 Earnings Call | Thu, Mar 07, 2019 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +5.7% |
| Q2 2026 | Aug 6, 2026 · After close | +0.4% |
| Q1 2026 | May 7, 2026 · After close | +1.9% |
| Q4 2025 | Mar 2, 2026 | −3.8% |
| Q3 2025 | Nov 10, 2025 · After close | +7.5% |
| Q2 2025 | Aug 7, 2025 · After close | −2.6% |
| Q1 2025 | May 8, 2025 · After close | −6.1% |
| Q4 2024 | Feb 24, 2025 · Before open | −5.0% |
| Q3 2024 | Nov 6, 2024 · After close | −4.2% |
| Q2 2024 | Aug 8, 2024 · After close | +0.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | +1.3% |
| Q4 2023 | Feb 26, 2024 · Before open | +27.8% |
| Q3 2023 | Nov 2, 2023 · After close | +8.2% |
| Q2 2023 | Aug 8, 2023 · After close | −5.8% |
| Q1 2023 | May 4, 2023 · After close | +5.7% |
| Q4 2022 | Feb 28, 2023 · After close | +8.5% |
| Q3 2022 | Nov 9, 2022 · After close | +16.0% |
| Q2 2022 | Aug 8, 2022 · After close | −5.8% |
| Q1 2022 | May 5, 2022 · After close | −5.0% |
| Q4 2021 | Feb 28, 2022 · After close | +5.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 21 slides | Sep 22, 2026 |
| Technical Presentation (June 2026) | Technical | 13 slides | June 2026 |
| Technical Presentation (June 2026) | Technical | 10 slides | June 2026 |
| EAACI Congress 2025 | Conference | 14 slides | Jun 13, 2025 |
| European Academy of Dermatology and Venereology (EADV 2024) | Conference | 16 slides | 2024 |
| FY2021 Earnings Presentation | Earnings | 25 slides | February 2022 |
| FY2014 Earnings Presentation | Earnings | 19 slides | Feb 24, 2015 |
| Technical Presentation (November 2013) | Technical | 31 slides | Nov 25, 2013 |
| Technical Presentation (November 2013) | Technical | 20 slides | November 2013 |
| FY2012 Earnings Presentation | Earnings | 12 slides | Mar 7, 2013 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2013) | Investor deck | 27 slides | Jan 7, 2013 |
| Technical Presentation (May 2012) | Technical | 16 slides | May 24, 2012 |
| Merger or Acquisition (June 2009) | Merger or acquisition | 17 slides | Jun 9, 2009 |
| Technical Presentation (June 2009) | Technical | 23 slides | Jun 2, 2009 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54M | 7.02M | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.7M | 6.79M |
| Cost of revenue | 200.0K | 200.0K | 300.0K | 100.0K | 100.0K | 200.0K | 100.0K | 700.0K | 700.0K | 1.60M |
| Gross profit | 1.34M | 6.82M | 6.58M | 2.26M | 4.55M | 7.22M | 3.47M | 8.84M | 12.0M | 5.19M |
| Research and development | 245.1M | 163.6M | 118.0M | 82.3M | 53.3M | 42.5M | 42.7M | 66.4M | 96.2M | 102.7M |
| Operating income | -287.4M | -195.1M | -154.5M | -115.2M | -71.2M | -63.4M | -55.0M | -156.4M | -121.5M | -132.9M |
| Depreciation and amortization | 3.38M | 3.18M | 3.01M | 2.90M | 3.07M | 3.93M | 4.86M | 3.58M | 4.41M | 3.10M |
| EBITDA | -284.0M | -191.9M | -151.5M | -112.3M | -68.2M | -59.4M | -50.2M | -152.9M | -117.1M | -129.8M |
| Income before tax | -258.8M | -157.9M | -141.4M | -112.3M | -70.7M | -60.9M | -50.9M | -151.9M | -117.3M | -128.5M |
| Income tax | 0 | 0 | 0 | -227.0K | -1.17M | -765.0K | -24.3M | |||
| Net income | -258.8M | -157.9M | -141.4M | -112.3M | -70.5M | -59.8M | -50.9M | -151.2M | -93.0M | -128.5M |
| Earnings per share, basic | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | -14.48 | -10.86 | -18.99 |
| Earnings per share, diluted | -3.90 | -2.45 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | -14.48 | -10.86 | -18.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 28.9M | 28.4M | 34.8M | 29.4M | 39.1M | 43.8M | 11.2M | 24.3M | 40.3M | 42.5M |
| Short-term investments | 489.7M | 696.9M | 388.8M | 275.5M | 369.1M | 150.6M | 53.2M | 69.7M | 99.1M | 147.3M |
| Current assets | 534.7M | 747.2M | 431.7M | 317.7M | 410.8M | 197.8M | 66.7M | 99.1M | 144.8M | 195.6M |
| Property, plant and equipment | 5.33M | 4.35M | 4.06M | 3.75M | 3.55M | 3.81M | 4.03M | 6.11M | 10.4M | 13.2M |
| Goodwill | 91.0M | 91.0M | ||||||||
| Total assets | 583.0M | 792.3M | 465.6M | 352.7M | 444.7M | 235.8M | 122.9M | 155.8M | 315.6M | 383.4M |
| Accounts payable | 1.18M | 3.27M | 3.49M | 3.34M | 1.23M | 1.05M | 1.17M | 1.07M | 1.72M | 1.74M |
| Current liabilities | 51.0M | 39.5M | 31.1M | 18.6M | 16.5M | 14.2M | 11.6M | 12.6M | 27.7M | 35.2M |
| Total liabilities | 55.8M | 45.3M | 36.5M | 26.5M | 25.2M | 26.5M | 28.9M | 31.7M | 79.3M | 117.9M |
| Shareholders' equity | 527.2M | 747.0M | 429.2M | 326.2M | 419.5M | 209.4M | 94.0M | 124.1M | 236.4M | 265.4M |
| Shares outstanding | 66.5M | 66.4M | 55.9M | 47.2M | 46.7M | 39.6M | 17.0M | 12.0M | 9.23M | 120.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -210.9M | -157.8M | -107.3M | -103.7M | -60.9M | -40.4M | -46.4M | -75.2M | -99.9M | -113.0M |
| Capital spending | -2.71M | -1.92M | -1.82M | -1.83M | -1.25M | -1.55M | -731.0K | -813.0K | -1.79M | -2.75M |
| Free cash flow | -213.7M | -159.7M | -109.1M | -105.6M | -62.2M | -42.0M | -47.1M | -76.0M | -101.7M | -115.8M |
| Cash from investing | 209.1M | -290.1M | -105.8M | 89.9M | -216.2M | -98.2M | 17.1M | 29.8M | 46.5M | 68.9M |
| Cash from financing | 2.39M | 441.4M | 218.5M | 4.08M | 272.4M | 171.2M | 16.3M | 29.4M | 51.3M | 14.5M |
| Change in cash | 515.0K | -6.46M | 5.38M | -9.71M | -4.69M | 32.6M | -13.1M | -16.0M | -2.17M | -29.6M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 26, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 424B5 · Prospectus | Apr 2, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 10, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 19, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 6, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 21, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 21, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 10, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 30, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 1, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 1, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 28, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 26, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Nov 8, 2023 | Offer document | SEC |
| 424B5 · Prospectus | Nov 7, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| S-3ASR · Registration statement | Nov 3, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| S-8 · Registration statement for employee plans | Jun 21, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Celldex Therapeutics, Inc.’s releases · as of Oct 28, 2026
- Common shares
- 78,545,051
- Fully diluted
- 78,545,051
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 78,545,051 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 78,545,051 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Denice Torres Other companies: Seaport Therapeutics, Inc. (Board Member · Since at least Apr 30, 2026); Glaukos Corporation (Director · Since at least Mar 1, 2021); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past); Surface Oncology Inc (Director · Jul 6, 2021 – Jun 8, 2022 · Past); Karuna Therapeutics Inc (Director · Dec 22, 2020 – Mar 18, 2024 · Past); Bluebird bio Inc (Director · Aug 10, 2020 – Nov 11, 2021 · Past) | Chief Executive Officer; The Ignited Company · Since at least Jun 5, 2025 |
| Timothy M Shannon Other companies: Rallybio Corporation (Director · Jul 28, 2021 – Jan 3, 2022 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – Jun 7, 2023 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 13, 2019 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Nov 29, 2016 · Past); Curagen Corp (Former President and CEO, Director · May 25, 2007 – Oct 1, 2009 · Past) | Director · Oct 1, 2009 – Jun 4, 2014 · Past |
| Richard A. van den Broek Other companies: Corvus Pharmaceuticals, Inc. (Board Member · Since at least Apr 8, 2025); Pulse Biosciences, Inc (Director · Since at least Aug 6, 2020); PhaseBio Pharmaceuticals Inc (Director · Feb 27, 2019 – May 19, 2023 · Past); Pharmacyclics Inc (Director · Oct 3, 2011 – May 26, 2015 · Past) | Director · Dec 17, 2014 – Jun 8, 2016 · Past |
| Rita Jain Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); SAB Biotherapeutics, Inc. (Director · Since at least Jan 5, 2026); Avalo Therapeutics, Inc. (Director · Since at least Jun 17, 2025); AnaptysBio, Inc. (Director · Since at least Jan 3, 2024) | Director · Since at least Jun 13, 2024 |
| Herbert J. Conrad Other companies: Matinas BioPharma Holdings, Inc. (Director · Mar 1, 2017 – Nov 1, 2023 · Past); Arbutus Biopharma Corporation (Director · Mar 4, 2015 – Jun 19, 2018 · Past); Savient Pharmaceuticals Inc (Director · Dec 30, 2005 – Jun 8, 2010 · Past) | Director · Since at least Mar 7, 2008 |
| Keith L Brownlie Other companies: Cancer Genetics Inc (Director · Jul 24, 2013 – May 22, 2014 · Past); Phio Pharmaceuticals Corp. (Director · Mar 1, 2013 – Feb 13, 2019 · Past); Soligenix, Inc. (Director · Jun 21, 2012 – Sep 27, 2018 · Past) | Director · Since at least Jun 15, 2017 |
| George O. Elston Other companies: EyePoint, Inc. (Executive Vice President, Chief Financial Officer · Since at least Nov 14, 2019); Juniper Pharmaceuticals Inc (Chief Financial Officer · Oct 1, 2014 – Aug 31, 2016 · Past) | Director · Jun 20, 2012 – Jun 8, 2016 · Past |
| Gerald PhD McMahon Other companies: Harpoon Therapeutics Inc (President and CEO, Director · Feb 7, 2019 – Jan 28, 2021 · Past); Oncotelic Therapeutics Inc (Director · Sep 2, 2011 – Jun 1, 2016 · Past) | Director · Dec 14, 2016 – Dec 3, 2018 · Past |
| Teri Lawver Other companies: Altimmune, Inc. (Director · Since at least Feb 24, 2025); DexCom, Inc. (EVP Chief Commercial Officer · Jan 9, 2023 – Mar 12, 2024 · Past) | Senior Vice President, Chief Commercial Officer · Since at least Nov 10, 2025 |
| Cheryl L. Cohen Other companies: ImmunityBio, Inc. (Director · Since at least Jun 11, 2024) | Director · Since at least Jun 13, 2024 |
All 31 people
| Person | Seat |
|---|---|
| Diane C. Young Other companies: Oncternal Therapeutics Inc (VP, Chief Medical Officer · Jul 13, 2015 – Jul 13, 2018 · Past) | Senior Vice President and Chief Medical Officer · Since at least Jul 8, 2019 |
| Garry A. Neil Other companies: Avalo Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Aug 13, 2024) | Director · Since at least Jun 13, 2024 |
| James J Marino Other companies: Traws Pharma, Inc. (Director · Nov 24, 2020 – Aug 10, 2023 · Past) | Director · Since at least Jun 17, 2021 |
| Larry Ellberger Other companies: Omrix Biopharmaceuticals Inc (Director · Aug 7, 2006 – Sep 4, 2008 · Past) | Director · May 25, 2006 – Jun 13, 2018 · Past |
| Rajesh R Parekh Other companies: Aura Biosciences, Inc. (Director · Oct 28, 2021 – Jun 7, 2023 · Past) | Director · Dec 23, 2009 – Sep 22, 2010 · Past |
| Thomas Andrew Davis Other companies: GenVec Inc (Chief Medical Officer · Nov 22, 2005 – Jan 18, 2006 · Past) | Executive VP & CMO · Mar 7, 2008 – Jun 15, 2017 · Past |
| Anthony S. Marucci | Founder, President, Chief Executive Officer and Director · Since at least Jan 6, 2009 |
| Elizabeth Crowley | Senior Vice President, Chief Product Development Officer · Since at least May 30, 2024 |
| Elizabeth Higgins | Executive Director, Investor Relations & Corporate Communications · Since at least Sep 22, 2026 |
| Freddy A. Jimenez | Senior Vice President and General Counsel · Since at least Jan 1, 2021 |
| Harry H. Penner | Since at least Nov 4, 2026 |
| Harry Penner Jr | Director · Since at least May 25, 2006 |
| J Barrie Ward | Director · May 25, 2006 – May 25, 2006 · Past |
| Margo Heath-Chiozzi | Senior Vice President, Regulatory Affairs · Since at least Oct 3, 2017 |
| Richard M Wright | SR. VP & CCO · Jul 1, 2015 – Jun 13, 2024 · Past |
| Ronald A. Pepin | Senior Vice President and Chief Business Officer · Since at least Nov 4, 2026 |
| Sam Martin | Senior Vice President and Chief Financial Officer · Since at least Jul 15, 2026 |
| Samuel Bates Martin | SVP AND CFO · Since at least Jul 1, 2017 |
| Sarah Cavanaugh | Senior Vice President, Corporate Affairs and Administration · Since at least Sep 22, 2026 |
| Theresa LaVallee | SVP, Reg.& Precision Medicine · Nov 29, 2016 – Dec 14, 2016 · Past |
| Tibor Keler | EXECUTIVE VP & CSO · Since at least Jun 13, 2024 |
Log in to ask 6ix AI your own questions about Celldex Therapeutics, Inc.